OSLO, Norway, June 27, 2018 /PRNewswire/ --
A participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO)previous employee share option program, not being a primary insider, has exercised a total number of 41,246 options through exercise of a corresponding number of free-standing warrants. 10,413 of the shares are exercised at a strike price of NOK
Following exercise of the 41,246 free-standing warrants, the Company's registered share capital was increased by NOK 8,249.2 through issuance of 41,246 new shares, each with a nominal value of NOK 0.20, against payment of a total subscription price of NOK 1,196,603. Following the share capital increase the Company has a share capital of NOK 9,817,129.6 divided on 49,085,648 shares, each with a par value of NOK 0.20.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate Communications
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-increased-share-capital-following-exercise-of-employee-share-options-300673159.html
SOURCE Nordic Nanovector
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All